ATAtsushi Tanaka

Atsushi Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Atsushi Tanaka has a total of 860 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Autoimmune Hepatitis: 2026 Update

    by Kazumichi Abe, Atsushi Tanaka

    Kazumichi Abe, Atsushi Tanaka. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260326

  • Open Access

    Artificial intelligence predicts recurrent autoimmune hepatitis after liver transplantation in a multicenter cohort study

    by Mamatha Bhat, Yingji Sun, Praveen Manickavel, Saba Maleki, Vincenzo Ronca, Bettina E Hansen, Gideon Hirschfield, Saleh Elwir, Mohamad Alsaed, Piotr Milkiewicz, et al.

    Background: Autoimmune hepatitis (AIH) is an important indication for liver transplantation (LT), but recurrence affects over 30% of recipients, threatening long-term survival. Current strategies to prevent recurrence and progressive graft fibrosis remain suboptimal, with limited evidence to guide selection of immunosuppressive regimens. We aimed to develop a dynamic, individualized, artificial intelligence–powered model for post-transplant recurrent AIH. Methods: We conducted a multicenter, retrospective cohort study of 706 patients who underwent LT for AIH between January 1987 and June 2020 at 33 centers in North America, South America, Europe, and Asia. We trained 4 predictive machine learning models—Logistic Regression, Random Forest, XGBoost, and Gradient Boost—to predict recurrent AIH (rAIH) using 62 clinical and laboratory variables, including demographic, biochemical features, and immunosuppressive drugs up to 1-year post-transplant. Feature importance was assessed using SHapley Additive exPlanations (SHAP) to enable interpretability at both individual and population levels. Results: AIH recurred in 16.5% of patients after LT. SHAP analysis identified younger age at LT, higher necroinflammatory activity in the explanted liver, and elevated MELD score at LT as key predictors of rAIH in the overall population. Tacrolimus-based therapy was associated with a lower risk of recurrence, while cyclosporine use conferred a higher risk. The addition of long-term prednisone to a regimen of tacrolimus and mycophenolate mofetil did not provide additional protective effect against rAIH. Conclusions: Our AI-powered clinical decision model provides personalized prediction of post-transplant rAIH. While it offers insight into modifiable and non-modifiable predictors, prospective validation is required before informing immunosuppressive decisions.

  • Open Access

    Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow‐Up

    by Akihito Takeuchi, Atsumasa Komori, Kazuhito Kawata, Osamu Yoshida, Kazunari Tanaka, Kazumichi Abe, Yukihisa Fujinaga, Tadashi Namisaki, Naruhiro Kimura, Tomohiro Katsumi, et al.

    Background and Aims: Primary biliary cholangitis (PBC) frequently impairs health‐related quality of life (HRQOL); however, longitudinal changes in symptoms and their relationship with prognosis remain unclear. We aimed to elucidate the current status of symptoms and HRQOL in Japanese patients with PBC, evaluate 10‐year changes in PBC‐40 scores, and examine associations with long‐term outcomes. Methods: This multicenter observational study comprised three analyses: (i) a 2025 cross‐sectional study assessing associations between clinical parameters, PBC‐40 (symptom indicators), and EQ‐5D‐5 L (HRQOL indicators); (ii) a longitudinal PBC‐40 study comparing scores from 2015 to 2025; and (iii) a longitudinal outcome study evaluating 2015 PBC‐40 scores and clinical parameters in relation to survival through 2025. Results: In 2025%, 20%–50% of all patients ( n = 239) had moderate/severe PBC‐40 scores in each domain. EQ‐5D‐5L scores were significantly lower in women < 59 years versus general population, with multivariable analysis identifying itch, fatigue, and social domains as independent contributors to impaired HRQOL. Across a 10‐year follow‐up, overall significant deterioration was observed in symptoms ( p = 0.0015), itch ( p = 0.0039), and cognitive ( p = 0.0011) domains, while interindividual variability was greatest in itch and emotional and smallest in symptoms. In longitudinal outcome study ( n = 410), no PBC‐40 domain predicted death or liver transplantation. Conclusions: HRQOL in patients with PBC was significantly impaired in younger female. Over 10 years, overall and interindividual changes in domain scores greatly varied, suggesting that symptom burdens are driven by heterogeneous underlying mechanisms. HRQOL impairment represents distinct dimensions of disease impact in PBC, independently of long‐term outcomes.

  • Open Access

    Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis

    by Ryohei Tanigawa, Yoshiyuki Ueno, Hirokazu Takahashi, Ayumi Saito, Hideki Suganami, Atsushi Tanaka

    Background and Aim: Pemafibrate, a selective PPARα modulator (SPPARMα), improves cholestatic liver enzymes in primary biliary cholangitis (PBC). However, whether these effects depend on PBC‐specific autoimmune mechanisms or reflect broader anti‐cholestatic actions remains unclear. This study evaluated the effects of pemafibrate on cholestatic markers by PBC status and explored bile acid and immunological changes in patients with PBC. Methods: This post hoc analysis used data from a 52‐week phase III study of pemafibrate in patients with hypertriglyceridemia, including 9 with PBC. Cholestatic markers (ALP, total bilirubin, GGT, and LAP) were assessed serially. Linear regression examined associations between baseline levels and response by PBC status. In patients with PBC, bile acids, FGF19, FGF21, C4, IgM, IgG, and M2BPGi were also evaluated. Results: Pemafibrate significantly reduced all cholestatic markers from week 4–52, regardless of the presence of PBC. Greater reductions were observed in patients with higher baseline levels. In patients with PBC, C4 decreased without significant change in FGF19, suggesting suppression of de novo bile acid synthesis independent of intestinal feedback. The bile acid profile shifted toward a more hydrophilic composition with reduced hydrophobic species. IgM, IgG, and M2BPGi decreased, whereas FGF21 increased. Conclusions: Pemafibrate improved cholestatic markers in a baseline‐dependent manner, regardless of the presence of PBC, suggesting mechanisms beyond PBC‐specific pathology. These findings support a broader anti‐cholestatic effect, potentially mediated by coordinated modulation of bile acid metabolism and immunological activity through PPARα activation. Trial Registration: The trials were registered at ClinicalTrials.gov under the identifiers NCT04716595


  • Reply to ‘The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view’

    by Christophe Corpechot, Maria-Carlota Londoño, Alejandra Villamil, Henriette Ytting, Atsushi Tanaka, Ulrich Beuers


  • Open Access

    Guidance for Liver Rehabilitation in Chronic Liver Disease

    by Shuji Terai, Hiroteru Kamimura, Yoichi Hiasa, Norio Akuta, Toru Ishikawa, Yuichiro Eguchi, Hironao Okubo, Takumi Kawaguchi, Miwa Kawanaka, Tatsuo Kanda, et al.

    In April 2023, the Japan Society of Hepatology published its official guidelines on liver rehabilitation for chronic liver disease. In this article, we summarize the current evidence on the role of liver rehabilitation in slowing the progression of chronic liver disease, particularly metabolic dysfunction‐associated steatotic liver disease (MASLD), liver cirrhosis, and hepatocellular carcinoma (HCC). Specifically, we outline the following: (1) the definition of liver rehabilitation and its target population; (2) exercise therapy in liver rehabilitation according to disease state; (3) considerations for patients with complications; (4) nutritional therapy in liver rehabilitation; and (5) potential economic benefits. Liver rehabilitation represents a novel therapeutic approach for patients with chronic liver disease, and this guidance aims to promote high‐quality clinical research and strengthen the evidence base for its application.


  • Open Access

    The Prognostic Utility of Quantitative Magnetic Resonance Cholangiopancreatography in Patients With PSC: A Systematic Review With Structured Evidence Synthesis

    by Raj Vuppalanchi, Fatih Akisik, Michele Pansini, Emma L. Culver, Atsushi Tanaka, Daniel S. Pratt, Elizabeth Shumbayawonda, Mukesh Harisinghani

    Background: Magnetic resonance cholangiopancreatography (MRCP) is used in the diagnosis and management of primary sclerosing cholangitis (PSC). However, MRCP is subjective, and guidelines state that there is insufficient evidence to recommend MRCP as a prognostic tool. EASL-PSC guidelines have identified quantitative MRCP (MRCP+) as having promising utility for risk assessment and prediction of clinical outcomes. We conducted a systematic review to determine the clinical utility of MRCP+ metrics for the management of patients with PSC. Methods: We systematically searched PubMed and MEDLINE for cohort studies reporting on MRCP+ metrics associated with risk prediction, clinical outcomes, and disease progression published between January 2019 and May 2024. Studies reporting on adults with diagnosed PSC with paired MRCP were selected. There were no limitations on the type of study (retrospective/prospective). Studies reporting on only qualitative assessment of MRCP were excluded. Results: Six manuscripts with 512 subjects met the study criteria. For risk prediction and disease progression, 4 articles reported 21 unique MRCP+ metrics, which were significantly associated with the Amsterdam-Oxford model and the MAYO risk score. MRCP+ metrics had AUC ranging 0.65 to 0.87 and hazard ratios ranging 0.96 to 17.79 for the prediction of adverse outcomes, including liver transplantation, death, hepatic decompensation, biliary complications, and cholangiocarcinoma. Associations between biochemical markers of liver function (alkaline phosphatase, bilirubin, aspartate aminotransferase, gamma glutamyl transferase, and albumin) ranged -0.42≤ R ≤0.48. Conclusion: MRCP+ metrics have clinical utility to support patient management alongside addressing key gaps, including standardising MRCP assessment, early detection of disease, and quantification of risk.


  • Pediatric Acute Liver Failure in Japan: Nationwide Survey Based on a National Classification Framework

    by Hajime Uchida, Ayano Inui, Seisuke Sakamoto, Mureo Kasahara, Nobuaki Nakayama, Atsushi Tanaka, Satoshi Mochida

    Objectives: Acute pediatric liver failure (ALF) is a rare but life‐threatening condition. This nationwide retrospective study aimed to characterize the clinical features, etiologies, management strategies, and outcomes of pediatric noncomatose and comatose ALF in Japan and to evaluate the utility of an early liver transplantation (LT) indication scoring system in this population. Methods: We reviewed pediatric cases of noncomatose and comatose ALF reported in a national registry between 2016 and 2021. Based on the Japanese criteria, patients were classified into noncomatose and comatose ALF groups. Subgroup analyses were carried out based on age, etiology, and outcomes. Results: A total of 136 patients (median age, 15.8 months) were included. Among the 136 patients, 48 (35.3%) were classified as noncomatose ALF and 88 (64.7%) as comatose ALF. Transplant‐free survival was significantly higher in noncomatose ALF (66.7%) than in comatose ALF (28.4%) ( p < 0.001). Patients with circulatory failure had a markedly worse prognosis, a high mortality rate (55.2%), and did not undergo LT. Infants had significantly lower transplant‐free survival rates than older children (31.6% vs. 49.4% and p = 0.052). Survivors ( n = 57) had higher platelet counts, lower bilirubin levels, and less liver atrophy patients who died or underwent LT ( n = 79). The prognostic score correlated with outcomes and demonstrated a strong discriminative ability for predicting transplant‐free survival (AUC 0.729; sensitivity 32.5% and specificity 92.9%). Conclusion: Age, etiology, and early prognostic scoring may appropriately guide clinical decisions. These findings underscore the need for pediatric‐specific prognostic tools and support the refinement of pediatric LT selection criteria.

  • Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025

    by Atsushi Tanaka, Sombat Treeprasertsuk, Ming-Ling Chang, Soek-Siam Tan, Cumali Efe, Sook-Hyang Jeong, Xiong Ma, Martin Weltman, Hiroyuki Isayama, Jidong Jia

    Background and Aims Autoimmune liver diseases (AILD) have historically been considered uncommon in the Asia–Pacific region, where viral hepatitis has predominated as the leading cause of chronic liver disease. However, their recognition and clinical relevance have increased substantially in recent years, mirroring global epidemiologic trends. This proceedings report summarizes the educational course on AILD held during the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) in 2025, highlighting contemporary insights into disease burden, diagnosis, and management across diverse populations. Methods International experts presented updated evidence and region-specific considerations concerning autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and IgG4-related sclerosing cholangitis. Key advances in risk stratification, imaging, serology, patient-reported outcome measures (PROMs), and emerging therapeutics were synthesized. Results Important updates included improved understanding of acute presentations of AIH, evolving risk stratification and second-line pharmacologic approaches in PBC, and advances in PSC diagnostics incorporating novel imaging modalities and emerging autoantibodies. The unique clinical phenotype and steroid responsiveness of IgG4-related sclerosing cholangitis were also emphasized. Increasing incorporation of PROMs into clinical practice and trials, as well as progress in targeted therapies—such as peroxisome proliferator-activated receptor agonists, farnesoid X receptor agonists, and ileal bile acid transporter inhibitors—reflects a shift toward precision medicine and improved quality of life. Conclusions AILD represents a growing clinical challenge in the Asia–Pacific region. Earlier recognition, individualized treatment strategies, and strengthened multinational collaboration are essential to address unmet diagnostic and therapeutic needs and to improve long-term outcomes.


  • Open Access

    Optimizing clinic consultations in primary biliary cholangitis: International consensus recommendations

    by Heike Bantel, Gideon M. Hirschfield, David E. Jones, Kris V. Kowdley, Ana Lleo, Robert Mitchell-Thain, Ann Moore, Carol Roberts, Atsushi Tanaka

    Background: There is variability in primary biliary cholangitis (PBC) care delivery in practice, which can negatively impact disease management and patients’ quality of life. Patient–provider consultations are key to ensure optimal and comprehensive disease management; however, the quality and substance of this interaction may vary. A Delphi study was carried out to provide consensus recommendations to improve and standardize consultations between providers and patients with PBC. Methods: An international survey of 151 healthcare professionals was conducted with input from 9 PBC experts (6 physicians, 1 patient, 1 patient advocate, and 1 nurse practitioner) who formed the Delphi panel. Informed by findings of the survey, the panel used Delphi methodology to develop best practice recommendations with the aim of informing the broader care framework. Consensus was defined as ≥75% agreement among panel members. Results: We identified 15 best practice recommendations across 3 principal areas: “patient–provider discussions at diagnosis/first consultation,” “symptom assessment and ongoing management,” and “wider care and support.” These consensus-based recommendations are a resource for providers to help address patient needs around symptom burden, referrals to specialists other than hepatologists, and connection to patient support organizations. Conclusion: We provide specific recommendations for providers to optimize consultation for patients with PBC with the aim of improving care and patient satisfaction.